18 results about "Neuregulin" patented technology

To provide a method of treating a patient with chronic heart failure using a medicament comprising neuregulin.SOLUTION: A companion diagnostic test is first performed on each patient prior to treatment, and the appropriate treatment is provided to each patient according to the companion diagnostic test results. If the test results are within a preferred therapeutic range for treatment, the patient is suitable for treatment of heart failure by administration of an effective amount of neuregulin.SELECTED DRAWING: None

Disclosed is a use of recombinant human neuregulin derivatives in preparing a medicine for preventing, treating, or reducing the progression of cardiovascular diseases in mammals. In particular, the present invention relates to a novel recombinant human NRG-FC protein and a use thereof in the treatment of cardiovascular diseases. The protein has a prolonged half-life and enhanced biological activity.

The present application relates to a culture medium for the culture of intestinal organoids characterized in that it comprises neuregulin 1 (NRG1) and all-trans retinoic acid (atRA). It also relates to a method using this medium to culture intestinal organoids.

The present invention relates to doses and dosing regimens of an NRG4 compound in the treatment of cardiovascular disease (CVD) related conditions, including heart failure (HF).

Provided herein are methods and compositions for treating cancer, particularly the methods and compositions comprising a neuregulin 4 (NRG4) polypeptide.

The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Cardiac Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the heart. Also disclosed are subsequent generations of this Cardiac Targeting Peptide with improved, higher efficiency of cardiac uptake for CTP-mediated delivery of antiarrhythmics subjects for treating Atrial fibrillation or Ventricular fibrillation, CTP-mediated delivery of neuregulin-1β for treating systolic heart failure (SHF), and Szeto-Schiller peptides for treatment of diastolic congestive heart failure, among other applications.

This invention provides the application of neuregulin protein in the manufacture of drugs for preventing, treating, or delaying human heart failure, and methods for using such drugs. [Solution] The method includes: first examining the patient before treatment, wherein the examination includes detecting plasma levels of NT-proBNP or BNP; and subsequently providing appropriate treatment based on the examination results. If the examination results are within the optimal therapeutic range, the patient is suitable for treatment of heart failure by administering an effective dose of Neureglin.

The invention discloses a culture medium of a breast cancer organoid, a culture method of the culture medium and application of the culture medium in drug detection, and relates to the technical field of cell and organoid culture, the culture medium of the breast cancer organoid comprises a basic culture medium and culture medium additives, and the culture medium additives comprise B-27, Neuregulin-1, Primocin, Y-27632 didrochloride, EGF, A83-01, N-Acetylcysteine and Nicotinamide; a method for culturing the breast cancer organoid by using the culture medium for the breast cancer organoid; the culture medium of the breast cancer organoid is applied to drug detection; by adopting the culture medium provided by the invention to culture the breast cancer organoid, the culture success rate and proliferation rate of the breast cancer organoid in the in-vitro culture process are improved, and the culture and drug detection period of the breast cancer organoid is shortened.

Disclosed is a use of recombinant human neuregulin derivatives in preparing a medicine for preventing, treating, or reducing the progression of cardiovascular diseases in mammals. In particular, the present invention relates to a novel recombinant human NRG-FC protein and a use thereof in the treatment of cardiovascular diseases. The protein has a prolonged half-life and enhanced biological activity.

The present invention relates to neuregulin positively dependent anti-human-HER3 antibodies comprising (i) a heavy chain wherein the variable domain has at least 90% or 95% identity with the amino acid sequence set forth as SEQ ID NO: 1 and (ii) a light chain wherein the variable domain has at least 90% or 95% identity with the amino acid sequence set forth as SEQ ID NO: 2. An immunoconjugate comprising an antibody of the invention or a fragment thereof, a nucleic acid sequence encoding an antibody of the invention or a fragment thereof, a vector as well as a host cell, a pharmaceutical composition comprising it, as well as their pharmaceutical use, are also considered.

The invention relates to the field of neurological rehabilitation medicine, and particularly discloses application of task-oriented training in promoting functional recovery after spinal cord injury (SCI). The invention is based on the discovery that task-oriented training (such as single globule grasping training) can activate an NRG1 / ErbB4 signaling pathway by up-regulating the phosphorylation level of neuro-regulatory protein-1 (NRG1) and a receptor ErbB4 of the NRG1, thereby promoting regenerative cortical spinal bundle (CST) axons and spinal motor neurons to form functional excitatory synapses and inducing the conversion of synaptic phenotypes to excitatory. The invention provides a treatment method including task-oriented training and a combined strategy for combined application of the treatment method and a treatment method for activating endogenous axon regeneration capacity (such as by inhibiting PTEN expression), the treatment method is used for improving upper limb movement dysfunction after spinal cord injury, particularly after neck injury, and a new scheme is provided for clinical treatment.

Described herein, inter alia, are compositions of HERS ligands comprising degradation-increasing moiety, and compositions and methods for treating diseases associated with HERS activity, including cancer, in a patient in need of such treatment using the same. Further disclosed methods of treating a disease associated with EGFR activity, HER2 activity, HER4 activity, c-MET activity, RISK activity, MEK activity, MARK activity, RAF activity, BRAF activity, AKT activity, RAS activity, KRAS activity, or neuregulin activity in a patient in need of such treatment.

The invention relates to rapid construction and application of a tissue-derived high-flux respiratory system organoid pathogen infection and drug screening model. The invention provides a kit or a composition for inducing formation of a single respiratory system organoid sphere. The kit or the composition comprises a matrigel-free culture medium containing the following components: (1) a BMP inhibitor, (2) a WNT agonist, (3) a ROCK inhibitor, (4) a TGF beta inhibitor, (5) a MAPK inhibitor, (6) a growth factor, (7) a neuregulin family protein and (8) one or more cell interaction promoters. The invention further provides a preparation method and application of the respiratory system organoid. The method provided by the invention can quickly construct the highly uniform and ciliary eversion respiratory tract type organ from the body tissue in a high-flux manner without relying on matrigel.

The present invention provides the application of neuregulin protein in the manufacture of a medicament for preventing, treating, or delaying human heart failure, and a method of using the medicament for preventing, treating, or delaying human heart failure. The method includes: first testing a patient prior to treatment, the testing including detecting plasma levels of NT-proBNP or BNP; and then providing appropriate treatment based on the test results. If the test results are within the optimal therapeutic range, the patient is suitable for treatment of heart failure by administering an effective dose of neuregulin.

Provided herein are recombinant fusion proteins comprising an active fragment of neuregulin-1 (NRG-1) fused to a monospecific ErbB3 (HER3) monoclonal antibody (mAb), and methods of using same to treat cardiovascular disease.

The disclosure relates to the field of neuregulin-1 (NRG1) fusions, methods for detecting such, identifying or diagnosing patients with such fusions and methods of treatment of a cancer, a tumor or an aberrant cell comprising an NRG1 fusion. Also, it relates to the field of therapeutic (human) compounds for the treatment of subjects with an ErbB-2 / ErbB-3 positive cancer that comprise a NRG1 fusion.

The present invention relates to neuregulin positively dependent anti-human-HER3 antibodies comprising (i) a heavy chain wherein the variable domain has at least 90% or 95% identity with the amino acid sequence set forth as SEQ ID NO: 1 and (ii) a light chain wherein the variable domain has at least 90% or 95% identity with the amino acid sequence set forth as SEQ ID NO: 2. An immunoconjugate comprising an antibody of the invention or a fragment thereof, a nucleic acid sequence encoding an antibody of the invention or a fragment thereof, a vector as well as a host cell, a pharmaceutical composition comprising it, as well as their pharmaceutical use, are also considered.